Page 280 - Haematologica Vol. 107 - September 2022

CASE REPORT
1Division of Hematology, Mayo Clinic, Rochester, MN; 2Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; 3Department of Radiology, Mayo Clinic, Jacksonville, FL; 4Division of Radiation Oncology, Mayo Clinic Health System, Albert Lea, MN and 5Division of Hematology- Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
Correspondence:
R. S. Go - go.ronald@mayo.edu
https://doi.org/10.3324/haematol.2022.280948
Received: February 27, 2022. Accepted: May 13, 2022. Prepublished: May 26, 2022.
©2022 Ferrata Storti Foundation Published under a CC BY-NC license
References
1. Tella SH, Kommalapati A, Rech KL, Go RS, Goyal G. Incidence, clinical features, and outcomes of Langerhans cell sarcoma in the United States. Clin Lymphoma Myeloma Leuk. 2019;19(7):441-446.
2. Yi W, Chen W-y, Yang T-x, Lan J-p, Liang W-n. Langerhans cell sarcoma arising from antecedent langerhans cell histiocytosis: A case report. Medicine. 2019;98(10):e14531.
3. Howard JE, Dwivedi RC, Masterson L, Jani P. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320-331.
4. Alhaj Moustafa M, Jiang L, Tun HW. Langerhans cell sarcoma: the Mayo Clinic experience with an extremely rare disease. J Clin Oncol. 2020;38(15_suppl):e19543.
5. Gounder MM, Solit DB, Tap WD. Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med. 2018;378(20):1945-1947.
6. Idbaih A, Mokhtari K, Emile JF, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology. 2014;83(16):1478-1480.
7. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously
Disclosures
No conflicts of interest to disclose.
Contributions
SZ, AR, GG and RSG conceived, wrote the first draft and modified the final draft; JPA, JRY, TK, KLR critically appraised the manuscript and approved the final draft of the manuscript.
Funding
The study was supported in part by the University of Iowa/Mayo Clinic Lymphoma SPORE CA97274 and the Walter B. Frommeyer, Jr., Fellowship Award in Investigative Medicine, University of Alabama at Birmingham (to GG).
Data-sharing statement
There is no relevant data to disclose.
untreated locally recurrent inoperable or metastatic triple- negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828.
8. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092.
9. Xu J, Sun HH, Fletcher CD, et al. Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders. Am J Surg Pathol. 2016;40(4):443-453.
10. Goyal G, Lau D, Nagle AM, et al. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms. Blood. 2019;133(14):1607-1610.
11. Lee M-y, Bernabe Ramirez C, Ramirez DC, Maki RG. Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDCS], histiocytic sarcoma [HS]). J Clin Oncol. 2020;38(Suppl 15):Se23574.
12. Dagoglu N, Karaman S, Caglar HB, Oral EN. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus. 2019;11(2):e4103.
Haematologica | 107 September 2022
2279